Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Cagrilintide

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Cagrilintide is a long-acting, investigational amylin and calcitonin receptor agonist developed for chronic weight management and metabolic regulation. It mimics the effects of the hormone amylin, which plays a role in satiety and gastric emptying. Cagrilintide is being studied both as monotherapy and in combination with semaglutide (a GLP-1 receptor agonist) under the investigational product name CagriSema .

    F act Table

    Formula

    C319H499N91O101S2

    License

    Not yet approved (investigational)

    Bioavailability

    ~45% (subcutaneous)

    Legal status

    Investigational (Phase 3 trials ongoing)

    Chemical Name

    Cagrilintide

    Elimination half-life

    ~168 hours (7 days)

    Dosage (Strength)

    Investigated in 0.3–4.5 mg weekly doses (subcutaneous)

    Pregnancy

    Unknown – not recommended due to lack of data

    Brands

    None (investigational)

    Protein binding

    Data not published

    PubChem CID

    137700278

    MedlinePlus

    Not assigned

    ChEBI

    Not assigned

    ATC code

    None (under development)

    DrugBank

    DB16357

    KEGG

    Not assigned

    Routes of administration

    Subcutaneous

    Directions

    Cagrilintide is administered via subcutaneous injection once weekly. Clinical trials have utilized a dose-escalation protocol, starting at 0.25 mg weekly and increasing incrementally to a maintenance dose of 2.4 mg weekly by week 17. When combined with semaglutide, the same titration schedule is applied. Administration should be under the guidance of a healthcare professional, with dosing tailored to individual patient response and tolerability.

    Ingredients

    Cagrilintide is formulated as an aqueous solution containing the active peptide at concentrations ranging from 0.1 to 20 mg/mL. The formulation includes buffer agents such as glutamic acid/glutamate (2–10 mM), lactic acid/lactate (2–35 mM), or acetic acid/acetate (2–10 mM), adjusted to a pH of approximately 4.0. Additional excipients may include glycerin, mannitol, propylene glycol, sorbitol, sucrose, or trehalose, with NaOH/HCl used for pH adjustment.

    Contraindications

    As cagrilintide is currently under investigation, comprehensive contraindication profiles are not fully established. However, patients with known hypersensitivity to cagrilintide or any component of the formulation should avoid its use. Caution is advised in individuals with a history of severe gastrointestinal disorders or pancreatitis. Use during pregnancy or lactation has not been studied and is therefore not recommended.

    Cautions

    Patients should be monitored for gastrointestinal adverse effects, particularly during dose escalation. Regular monitoring of renal function and hydration status is advised, especially in those with pre-existing renal impairment. The safety and efficacy of cagrilintide in pediatric populations have not been established. As with other weight management therapies, cagrilintide should be used in conjunction with a reduced-calorie diet and increased physical activity.

    Side Effects

    Common side effects observed in clinical trials include:

    • Nausea (up to 47%)
    • Injection site reactions (up to 43%)
    • Constipation (21%)
    • Fatigue (20%)
    • Vomiting (8%)
    • Headache (7%)
    • Diarrhea (7%)
    • Dyspepsia (4%)

    These adverse effects are generally mild to moderate in severity and tend to diminish over time. Patients should report any persistent or severe symptoms to their healthcare provider.

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14566

  • Product Reviews